PMC:7408073 / 221-616 JSONTXT

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T4","span":{"begin":168,"end":171},"obj":"Body_part"}],"attributes":[{"id":"A4","pred":"uberon_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/UBERON_0018229"}],"text":"S) pathways as specific targets in patients infected by SARS-CoV-2 in order to prevent positive feedback-loop mechanisms. Based purely on experimental studies in which RAS pathway inhibitors were administered in vivo to humans/rodents, a reasonable hypothesis of using inhibitors that block both ACE and ACE2 zinc metalloproteases and their downstream pathways in COVID-19 patients will be propo"}

{"project":"LitCovid-PubTator","denotations":[{"id":"21","span":{"begin":296,"end":299},"obj":"Gene"},{"id":"22","span":{"begin":304,"end":308},"obj":"Gene"},{"id":"25","span":{"begin":35,"end":43},"obj":"Species"},{"id":"26","span":{"begin":56,"end":66},"obj":"Species"},{"id":"27","span":{"begin":220,"end":226},"obj":"Species"},{"id":"28","span":{"begin":373,"end":381},"obj":"Species"},{"id":"31","span":{"begin":44,"end":52},"obj":"Disease"},{"id":"32","span":{"begin":364,"end":372},"obj":"Disease"}],"attributes":[{"id":"A21","pred":"tao:has_database_id","subj":"21","obj":"Gene:59272"},{"id":"A22","pred":"tao:has_database_id","subj":"22","obj":"Gene:59272"},{"id":"A25","pred":"tao:has_database_id","subj":"25","obj":"Tax:9606"},{"id":"A26","pred":"tao:has_database_id","subj":"26","obj":"Tax:2697049"},{"id":"A27","pred":"tao:has_database_id","subj":"27","obj":"Tax:9606"},{"id":"A28","pred":"tao:has_database_id","subj":"28","obj":"Tax:9606"},{"id":"A31","pred":"tao:has_database_id","subj":"31","obj":"MESH:D007239"},{"id":"A32","pred":"tao:has_database_id","subj":"32","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"S) pathways as specific targets in patients infected by SARS-CoV-2 in order to prevent positive feedback-loop mechanisms. Based purely on experimental studies in which RAS pathway inhibitors were administered in vivo to humans/rodents, a reasonable hypothesis of using inhibitors that block both ACE and ACE2 zinc metalloproteases and their downstream pathways in COVID-19 patients will be propo"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T2","span":{"begin":56,"end":64},"obj":"Disease"},{"id":"T3","span":{"begin":56,"end":60},"obj":"Disease"},{"id":"T4","span":{"begin":364,"end":372},"obj":"Disease"}],"attributes":[{"id":"A2","pred":"mondo_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A4","pred":"mondo_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"S) pathways as specific targets in patients infected by SARS-CoV-2 in order to prevent positive feedback-loop mechanisms. Based purely on experimental studies in which RAS pathway inhibitors were administered in vivo to humans/rodents, a reasonable hypothesis of using inhibitors that block both ACE and ACE2 zinc metalloproteases and their downstream pathways in COVID-19 patients will be propo"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T1177","span":{"begin":220,"end":226},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T48692","span":{"begin":236,"end":237},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"S) pathways as specific targets in patients infected by SARS-CoV-2 in order to prevent positive feedback-loop mechanisms. Based purely on experimental studies in which RAS pathway inhibitors were administered in vivo to humans/rodents, a reasonable hypothesis of using inhibitors that block both ACE and ACE2 zinc metalloproteases and their downstream pathways in COVID-19 patients will be propo"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T4","span":{"begin":168,"end":171},"obj":"Chemical"},{"id":"T5","span":{"begin":172,"end":190},"obj":"Chemical"},{"id":"T6","span":{"begin":180,"end":190},"obj":"Chemical"},{"id":"T7","span":{"begin":269,"end":279},"obj":"Chemical"},{"id":"T8","span":{"begin":309,"end":313},"obj":"Chemical"}],"attributes":[{"id":"A4","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_63620"},{"id":"A5","pred":"chebi_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/CHEBI_76932"},{"id":"A6","pred":"chebi_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A7","pred":"chebi_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A8","pred":"chebi_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/CHEBI_27363"},{"id":"A9","pred":"chebi_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/CHEBI_30185"}],"text":"S) pathways as specific targets in patients infected by SARS-CoV-2 in order to prevent positive feedback-loop mechanisms. Based purely on experimental studies in which RAS pathway inhibitors were administered in vivo to humans/rodents, a reasonable hypothesis of using inhibitors that block both ACE and ACE2 zinc metalloproteases and their downstream pathways in COVID-19 patients will be propo"}